Rapport Therapeutics announced positive topline results from a Phase 2a trial of its focal onset seizure medication RAP-219, achieving the primary endpoint by significantly reducing long seizure episodes. The study reported a 77.8% median reduction in clinical seizure frequency over 8 weeks, with 24% of participants seizure-free during treatment. Following the announcement, the company’s shares surged over 150% in premarket trading. The data enables advancement to Phase 3 clinical trials, marking a critical milestone in epilepsy drug development.